Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
72 Cards in this Set
- Front
- Back
Define drug
|
an article intended to be used in the diagnosis, mitigation, treatment or pevention of disease
|
|
define pharmacy
|
the preparation of drugs and their formulation into remedies
|
|
what does the DEA regulate?
|
controlled substances (drugs and chemicals)
|
|
what does the USDA regulate?
|
biologicals, such as vaccines
|
|
what does the EPA regulate?
|
pesticides- including those to be applied topically
|
|
what does the FDA regulate?
|
drugs
|
|
Pure Food and Drugs act
|
1906, prohibited interstate commerce in misbranded and adulterated food or drugs
|
|
Federal food, drug, and cosmetics act
|
1938. toxicity studies required, prohibits use of expired drugs, requires approval of New Animal Drug Application
|
|
Delaney Clause
|
1958, no substance which cuases cancer to animals may be added to food (including food producing animals)
|
|
Who was Frances Oldham Kelsey?
|
refused to authorize thalidomide for use in the US, was a reviewer for the FDA
|
|
Kefauver-Harris Amendment
|
1962: effort to evaluate the risk vs benefit ration. Required animal and in vitro research before clinical trials.
|
|
AMDUCA
|
1994: animal medicinal drug use clarifications act. Permits vets to use drugs for extralabel uses, while giving the FDA the authority to regulate those uses and to impose requirements to protect the public health
|
|
VCPR
|
veterinarian client patient relationship
|
|
components of a legal rx
|
date, name/address of patient/owner, drug name and dose, instructions to pharmacist, directions for usage, number of refills, vet info, DEA number
|
|
EBM
|
evidence based medicine- integration of best resarch evidence with clinical expertise and patient values
|
|
define: observational study
|
the investigator does not control the allocation of factors, greater potential for biases… include case series, case control and cohort studies
|
|
define: controlled experiments
|
the investigator does control the allocation of factors. Balanced/controlled by randomization. Supply strong evidence. Strongest = double blinded, randomized control clinical trial
|
|
schedule 1
|
high potential for abuse, no accepted medical use-- heroin, dihydromorphine, morphine methylsulfonate, lsd, marijuana, etc
|
|
schedule 2
|
high potential for abuse, but has accepted medical use. Abuse leads to dependence. Narcotics(cocaine, morphine, hydromorphone, methamphetamine, methadone, meperidine, etorphine), amobarbital, pentobarbital
|
|
schedule 3
|
less potential for abuse, narcotics (Combos with limited amounts or combinations of opium, morphine, ethylmorphine, codeine, dihydrocodeine, hydrocodone), ketamine, anabolic steroids
|
|
schedule 4
|
low potential for abuse- phenobarb, diazepam, butorphanol
|
|
schedule 5
|
preparations with low amounts of narcotics- mainly antitussives and antidiarrheals
|
|
law of mass action
|
k2/k1 = kd = [d][r]/[dr]
|
|
Kd
|
the concentration at which half of all receptors are occupied by the durg
|
|
K2 is ______ to the affinity of the drug for the receptor
|
inversely proportional
|
|
define agonist
|
drugs that have both affinity and intrinsic activity (ie, epi, acetylcholine, nicotime, morphine)
|
|
define partial agonist
|
the drug elicits a partial response, the max response is less than the max response generated by the full agonist. Has affinity for the rc, but less intrincsic activity than a full agonist
|
|
define inverse agonist
|
drug that bides to the receptor to suppress constitute activity
|
|
define antagonist
|
drugs that affinity for rc, but lack intrinsic activity. They block/reduce the effect of agonists in compet or noncompet manner (ie, diphenhydramine, atropine, spironolactone)
|
|
graded dose response curve
|
the relationship between dosage and the intensity of the response elicted in an individual animal or tissue
|
|
what does ED50 measure?
|
drug potency
|
|
what does Emax measure?
|
drug efficacy
|
|
quantal dose response-
|
the relationship between dosage and the percentge of the population responding in a similar matter
|
|
therapeutic index=
|
LD50/ED50
|
|
therapeutic ratio =
|
LD25/ED75
|
|
additive effect
|
A + B = A+B
|
|
synergistic effect
|
response to A and B coadministered is greater than A + B
|
|
define potentiation
|
an increase in potency of one drug caused by another drug that does not have the same phamacological effect (ie clavamox)
|
|
mixing agonist and antagomist-
|
will diminish the anticipated response. Compet-- inhibitory effect depends on concentrations of each. Noncompet- antagonism cannot be overcome with more agonist
|
|
define tolerance
|
the drug becomes less effective (elicts a lower effect at the same dose) with repeated use
|
|
define tachyphylaxis
|
pharmacodynamic tolerance that develops rapidly
|
|
up/down regulation of receptors
|
a change in maximal response due to a change in receptor numbers
|
|
speed of systemic exposure
|
IV>IO>inhalation>IM>SC>PO
|
|
Dispositional processes
|
pathways by which drugs travel throughout the body. Encompasses: dissolution, absorption, distribution and elimination (biotransformation and excretion)
|
|
What can move directly through the lipid membrane?
|
small, lipid soluble (uncharged, unionized, nonpolar, lipophilic) drugs
|
|
what can diffuse through protein channels?
|
very small, water soluble (charged ionized, polar hydrophlic) substances
|
|
Describe active transport through lipid membranes
|
ATP binding cassette, p-glycoprotein
absobs from the gut, excludes from the brain, excretes in liver and kidneys |
|
what is p-glycoprotein?
|
protective mechanism that pumps drugs out
|
|
small lipophliic molecules are ______ from the GI tract
|
readily absorbed
|
|
absorption is greatest in areas with greater _____ ___
|
surface area
|
|
acid drugs are trapped in ____ environments
|
basic
|
|
two factors that affect lipid solubility
|
inherent lipid solubility
degree of ionization |
|
factors affecting drug distribution
|
lipid solubility of the drug
tissue perfusion tissue capactity binding to plasma proteins |
|
drug distribution: high tissue perfusion
|
brain, kidney, liver, heart
|
|
drug distribution: medium tissue perfusion
|
muscle, skin
|
|
drug distribution: low tissue perfusion
|
fat, skeleton
|
|
two tissues with high capactity for drug distribution
|
muscle and fat
|
|
name five barrier restricted compartments
|
placenta, blood-brain, blood prostate, blood-ocular, bood-testes
|
|
two ways drugs can be excreted
|
intact (parent drug)
changed product (metabolite) |
|
methods of excretion
|
urine, bile, feces, breath, milk, sweat, tears, etc
|
|
what is the main goal of biotransformation?
|
increased excretion of substrates
|
|
which is excreted more rapidly, polar or nonpolar drugs?
|
polar
|
|
which is more polar, drug metabolites or parent drugs?
|
drug metabolites
|
|
what do nonsynthetic reactions do
|
oxidation, reduction or hydrolysis will reveal or introduce a functional group
|
|
what do synthetic reactions do
|
conjugation or attachment of an endogenous polar molecule to a functional group by glucuronidation, sulfate conjugation, glutathione conjugation, acetylation, methylation, amino acid conjugation
|
|
Phase 1 reactions
|
microsomal oxidation
nonmicrosomal oxidations |
|
types of synthetic reactions
|
glucuronidation, sulfation, amino acid conjugation, glutathione conjugation, glucose conjugation, acetylation, methylation
|
|
agents that induce the cytochrome p450 complex
|
phenobarb, rifampin
|
|
agents that inhibit the cytochrome p450 complex
|
ketoconazole, cimetidine
|
|
first pass effect affects drugs that are extensively metabolized by the
|
liver
|
|
prodrugs
|
metabolized to their active form, often in the liver or by plasma and intestinal esterases
|
|
renal excretion: glomerular filtration is inhibited by
|
plasma protein binding
|